TherapyX, Inc is Awarded Phase I Funding
Buffalo, NY-November 3, 2016 TherapyX is pleased to announce a new SBIR Phase I award to test its novel product, IL10NanoCap, a completely new nano encapsulated oral formulation of the key regulatory cytokine interleukin 10 (IL-10), in rodent models of inflammatory bowel disease. The NIH SBIR award, from the National Institute of Diabetes and Digestive and Kidney Diseases to Dr. Dominick L. Auci, MBA Ph.D., Vice President for Research and Development, aims at demonstrating proof of concept that orally administered IL10NanoCap can ameliorate established disease in several rodent models, to elucidate mechanism of action, and to provide preliminary pharmacotoxicology data.
“We are delighted with this new award ” said Dr. Dominick L. Auci, Vice President for Research and Development. “and excited about putting our new oral product, IL10NanoCap to the test in rodent models. We also continue the development of our two lead products, NGoXIMTM and TreXTAMTM towards clinical studies”
TherapyX, Inc. is developing a proprietary drug delivery system based on mild encapsulation of highly potent protein therapeutics into microparticles that preserves bioactivity, achieves controlled tissue specific release, reduced toxicity and shelf-stability. Its two lead products NGoXIMTM and TreXTAMTM are aimed at mucosal infections and inflammatory diseases, respectively. For more information on TherapyX contact the Company’s website at www.therapyxinc.com.